New European Directory Maps 487 Verified Psychedelic Treatment and Research Sites

PSA Media Team | October 30, 2026

In partnership with

Fuel the Future of Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate to The PSA Media Fund at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required

New European Directory Maps 487 Verified Psychedelic Treatment and Research Sites

As psychedelic access expands in the United States, European advocates and industry stakeholders ramp up efforts across the Atlantic

LISBON, Portugal — Navigating legal access to psychedelic-assisted therapy and ketamine treatment in Europe requires sorting through 27 national regulatory systems, a dozen languages, and a mix of clinical facts and clinic marketing. On Sept. 15, a free database called PsyAccess launched to consolidate that information, publishing 487 registry-verified records across 27 European countries.

Operating independently within Pink Elephant Group, the directory separates clinical care from experimental research. The 487 listings comprise 212 licensed esketamine centers, 129 clinical trial sites, 103 authorized psychedelic-assisted therapy providers, and 43 ketamine or ketamine-assisted psychotherapy clinics. Because the 129 trial sites involve research under a study protocol rather than available clinical care, the database identifies 358 providers where patients can currently receive treatment.

The map illustrates sharp geographic disparities between where psychedelic medicine is legal and where it is reachable. Among the 103 authorized psychedelic-assisted therapy providers, 101 operate in Switzerland under its per-patient authorization scheme, and two are German sites in an authorized psilocybin compassionate-use program. None of the other 25 countries in the directory have any providers in that category, and seven (Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, and Slovakia) have only one verified provider of any kind.

Still, targeted clinical and retreat pathways are expanding across the region. Germany's two authorized sites, the Central Institute of Mental Health in Mannheim and the OVID Clinic in Berlin, operate under a compassionate-use program approved in July 2025 for treatment-resistant depression. In the Czech Republic, a national medical psilocybin law took effect on Jan. 1, 2026, permitting psychiatrists at approved facilities to administer synthetic psilocybin alongside psychotherapy, with clinical rollout at the National Institute of Mental Health slated for late 2026. In Southern Europe, Ambio Life Sciences operates physician-led ibogaine treatment programs and retreats in Malta and Italy, providing medically supervised care for trauma, traumatic brain injury, and substance dependence in jurisdictions where ibogaine remains unscheduled. Outside the European Union, war-related trauma has accelerated clinical efforts in Ukraine, where nonprofits like Heal Ukraine Trauma support legal ketamine-assisted psychotherapy for veterans and the Ukrainian Psychedelic Research Association trains clinicians in MDMA-assisted therapy.

Broader efforts to harmonize access across the continent have moved slower. In January 2025, advocates launched PsychedeliCare, a European Citizens' Initiative urging the European Commission to establish unified standards and funding for psychedelic therapies. When signature collection closed in January 2026, the campaign had gathered 74,016 signatures, short of the one million required to trigger formal Commission action, leaving access governed by national rules.

Researchers note that this fragmented landscape leaves patients uncertain about the safeguards of services found online. "As interest in psychedelic medicine grows, patients face an increasingly complex landscape spanning authorised treatments, off-label clinical practice and investigational therapies available only through research," said Dr. Rayyan Zafar, a neuropsychopharmacologist and UKRI postdoctoral fellow. "Transparent, source-linked infrastructure that helps people understand what is genuinely available, and that clearly distinguishes clinical treatment from research participation, is an important step towards safer, better informed and more equitable access."

Clinicians warn that lacking centralized information can push patients toward unregulated settings. Dr. Christopher Gauci, an anaesthetist and intensive care specialist who administers ketamine treatments, said European patients often end up in unverified environments because they do not know where else to look. Òscar Parés, founder and CEO of Clínica Synaptica, added that individuals unable to find a clear path can turn to improvised options out of desperation. "Mental health care requires a baseline: a coordinated team, a clear ethical framework, and a safe environment," Parés said.

Unlike directories where clinics pay for placement, PsyAccess lists providers for free, and payment does not affect inclusion, ranking, or verification. Every entry requires at least two independent sources under its public verification methodology, including an official register wherever one exists, with source links printed on each listing. Records are re-checked every 90 days and deleted rather than labeled unverified if they cannot be proven.

Available in five languages, PsyAccess publishes its full dataset openly under a CC BY license and allows clinics to update or remove records via a provider portal. Tom McDonald, co-founder and board member at Clerkenwell Health, noted that while demand has grown over the past decade, patients still struggle to locate treatments with clinical oversight. "I expect the number of treatment centres will proliferate in the coming years as psychedelics reach approval, so a free and up-to-date directory will only increase in utility," McDonald said.

The PSA Media Fund

Until next time,

The Psychedelic State(s) of America Team